

# HYALURONIC ACID-COATED CAPECITABINE NANOSTRUCTURES FOR CD44 RECEPTOR-MEDIATED TARGETING IN BREAST CANCER THERAPY

Sruthi Laakshmi Mugundhan<sup>a</sup>, Mothilal Mohan<sup>a,\*</sup>

<sup>a</sup> Department of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur-603203, Chengalpattu, Tamil Nadu, India

\*Correspondence to:

Mothilal Mohan, Department of Pharmaceutics, SRM College of Pharmacy, SRM Institute of Science and Technology, Kattankulathur-603203, Chengalpattu, Tamil Nadu, India; E-mail: [mothilam@srmist.edu.in](mailto:mothilam@srmist.edu.in); [mothipharma78@gmail.com](mailto:mothipharma78@gmail.com)

## SUPPLEMENTARY DATA

### 1. Methods

#### 1.1. Experimental Design


**Table S1** represents the levels of independent variables selected for the design.

Independent variables	Levels		
	-1	0	+1
A : Saponin (mMol)	1	2.5	4
B : Glycerol (mMol)	1	2.5	4
C : Sonication Time (Mins)	15	30	45

### 2. Results and Discussion


#### 2.1. Drug - Excipient Compatibility studies

**Figure S1** represents the FTIR Spectrum of pure drug Capecitabine.



### Capecitabine

Table S2 represents the results and interpretation of FTIR spectrum of Capecitabine.




Structure of Capecitabine

WAVELENGTH ( $\text{cm}^{-1}$ )	FUNCTIONAL GROUP	INTERPRETATION
3510.45	Aromatic 1° amine, NH Stretch	Matches the -NH group in Capecitabine's pyrimidine ring


1919.17	Aromatic combination bands	Combination of vibrations from the aromatic rings in Capecitabine's structure
1689.64	Quinone or conjugated Ketone; Open-chain imino (-C=N-)	Corresponds to the -C=N group in the pyrimidine ring
1641.42	Open-chain imino (-C=N-); Amide	Matches the amide group (-CONH-) and pyrimidine imino group
1454.33	C=C-C Aromatic ring stretch	Matches aromatic stretches in the pyrimidine and phenyl rings
1375.25	Phenol or 3° alcohol	Matches the hydroxyl group (-OH) in the sugar moiety
1330.88	Aromatic 3° amine, CN stretch; Methyne C-H bend (>CH-)	Matches the C-N bonds in Capecitabine's nitrogenous base
1234.44	Aromatic ethers, Aryl - O - Stretch	Matches vibrations of C-O bonds in the ester and sugar moiety
1105.21	Cyclic ethers, large rings, C-O stretch; Aromatic C-H in-plane bend	Matches C-O bonds in the sugar moiety and aromatic C-H bonds
1078.21	Aromatic C-H in-plane bend; Aliphatic Fluoro compounds C-F stretch	Peak corresponds to aromatic C-H bending and C-F stretching
954.76	Aromatic C-H in-plane bend	Matches aromatic C-H bends in the pyrimidine ring and aromatic substituents
756.10	CH 1,3 Disubstitution (meta); Aromatic C-H out of plane bend	Matches meta-substituted aromatic rings in Capecitabine

**Figure S2** represents the FTIR Spectrum of physical mixture of Capecitabine and Hyaluronic acid.




**Capecitabine + HA**

**Figure S3** represents the FTIR Spectrum of physical mixture of Capecitabine and Saponin.




**Capecitabine + Saponin**



**Capecitabine + Glycerol**

Figure S4 represents the FTIR Spectrum of physical mixture of Capecitabine and Glycerol.



Figure S5 represents the FTIR Spectrum of physical mixture of Capecitabine and Vit-E TPGS.





**Capecitabine + Vit-E TPGS**

Figure S6 represents the FTIR Spectrum of Capecitabine-loaded micelles (CAP-M).

Figure S7 represents the FTIR Spectrum of Hyaluronic acid-coated Capecitabine-loaded micelles (HA-CAP-M).



**HA-CAP-M**



**CAP-M**

## 2.2. Optimization

**Table S3.** Analysis of variance for the quadratic polynomial model for Particle size, EE and *in vitro* drug release after 4 hours

Source	f-Value	p-value prob > f	
<b>Particle size (nm)</b>			
<b>Model</b>	50.34	0.0002	Significant
A-Saponin	286.60	< 0.0001	
B-Glycerol	14.02	0.0134	
C-Sonication Time	22.00	0.0054	
AB	0.2868	0.6152	
AC	2.10	0.2072	
BC	0.3485	0.5806	
A <sup>2</sup>	95.33	0.0002	
B <sup>2</sup>	13.26	0.0149	
C <sup>2</sup>	33.90	0.0021	
<b>EE (%)</b>			
<b>Model</b>	906.50	< 0.0001	significant
A-Saponin	7272.78	< 0.0001	
B-Glycerol	85.22	0.0003	
C-Sonication Time	0.5872	0.4781	
AB	10.77	0.0219	
AC	0.0004	0.9846	
BC	0.9642	0.3712	
A <sup>2</sup>	355.09	< 0.0001	
B <sup>2</sup>	317.28	< 0.0001	
C <sup>2</sup>	235.44	< 0.0001	
<b><i>In vitro</i> drug release after 4 hours (%)</b>			
<b>Model</b>	6.41	0.0273	significant
A-Saponin	30.26	0.0027	
B-Glycerol	2.95	0.1463	

C-Sonication Time	0.0664	0.8070
AB	0.5399	0.4955
AC	1.94	0.2224
BC	0.3749	0.5671
A <sup>2</sup>	3.97	0.1030
B <sup>2</sup>	12.92	0.0156
C <sup>2</sup>	7.70	0.0392

**Table S4.** Predicted models of Capecitabine-loaded micelles

<b>Models</b>	
<b>Particle size</b>	$= +17.48 - 9.84 A - 2.18 B - 2.73 C - 0.4400 A*B + 1.19 A*C + 0.4850 B*C + 8.35 A^2 + 3.11 B^2 + 4.98 C^2$
<b>Entrapment efficiency</b>	$= + 76.22 + 29.63 A + 3.21 B + 0.2662 C - 1.61 A*B + 0.0100 A*C + 0.4825 B*C - 9.64 A^2 - 9.11 B^2 - 7.85 C^2$
<b>Drug release after 4 hours</b>	$= +66.69 + 3.18 A + 0.9925 B + 0.1487 C - 0.6000 A*B + 1.14 A*C + 0.5000 B*C - 1.69 A^2 - 3.06 B^2 - 2.36 C^2$

**Table S5.** Results of regression analysis for responses (Particle size, EE and *in vitro* drug release)

Response	R-squared	Adj R- Squared	Adeq Precision	Lack of fit
Particle size	0.9891	0.9694	20.9185	0.15
EE (%)	0.9994	0.9983	81.8498	0.7873
<i>In vitro</i> drug release after 4 hours (%)	0.9203	0.7768	7.4459	0.1032

**Table S6.** Optimized values obtained from the RSM method and related experimental data at the optimum conditions



---

<b>Parameter</b>	<b>Predicted by RSM</b>	<b>Experimental Data</b>
<b>Particle size (nm)</b>	17.4767	17.8 ± 3.2
<b>Entrapment Efficiency (EE) (%)</b>	76.22	76.92 ± 2.41
<b><i>In vitro</i> drug release after 4 hours (%)</b>	66.6933	66.69 ± 3.43

---